FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

PDPL Share Price Discussion

Parenteral Drugs (India) Ltd.
NSE: PDPL | BSE: 524689 | ISIN: INE904D01019 | Sector: Pharmaceuticals and health care

PDPL Rating

0/5 (0 Ratings)
PDPL Share Price *
0 +0 (0%)
* (quote may be delayed)
Find answers to all your questions on live PDPL message board: Is PDPL buy or sell? Should I buy PDPL shares? Why are PDPL shares falling? Should I invest in PDPL stock?

PDPL Discussion Forum

@newsbot • Reputation: 2,356
Parenteral Drug Standalone June 2019 Net Sales at Rs 8.73 crore, down 17.55% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,356
Parenteral Drug Consolidated June 2019 Net Sales at Rs 8.72 crore, down 82.24% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,356
Like
reply
Reply
@newsbot • Reputation: 2,356
Like
reply
Reply
@newsbot • Reputation: 2,356
Like
reply
Reply
  • PDPL - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization25.2
    Enterprise Value685.93
    Price to Earnings44.41
    Price to Book Value4.67
    Return on Capital Employed-0.04
    Return on Equity0.24
    Face Value10
    Dividend YieldNA
  • PDPL Share Price - Technicals

    keyboard_arrow_down
    PDPL - 52 Week High₹15.5
    PDPL - 52 Week Low₹4
  • PDPL Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 284.955.44.55.4
    Jun 275.55.54.655.15
    Jun 264.85.554.655.25
    Jun 255.055.54.45.2
    Jun 244.655.64.65
  • PDPL Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹5.46
    30 Day Moving Average₹5.86
    50 Day Moving Average₹6.35
    100 Day Moving Average₹7.79
    200 Day Moving Average₹8.37
  • PDPL - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3352.19-0.37
    Operating Profit-16-34.62-0.54
    Profit Before Tax-119-125.23-0.05
    Net Income-96-113.31-0.15
  • PDPL - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds-447-4060.1
    Total Liabilities9871,170-0.16
    Total Assets539764-0.29
  • PDPL - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity14848.982.02
    Cash from Investing Activity-10.1-11
    Cash from Financing Activity-148-50.411.94
    Net Cash FlowNA-1.33-1
  • PDPL - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.13-0.12
    Return on Equity0.241.3
    Return on Capital Employed-0.04-0.09
  • PDPL - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.81
    3 Year CAGR Growth in Operating Profit-2.3
    3 Year CAGR Growth in EBIDTA-2.9
    3 Year CAGR Growth in Net Income-0.78
    3 Yr CAGR Growth - Diluted EPS-0.78
  • PDPL - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.82
    5 Year CAGR Growth in Operating Profit0.28
    5 Year CAGR Growth in EBIDTA-4.65
    5 Year CAGR Growth in Net Income-0.13
    3 Yr CAGR Growth - Diluted EPS0.02
  • PDPL - Recent News

    keyboard_arrow_down
    NewsBot
    Aug 6 9:48 AM
    Parenteral Drug Standalone June 2019 Net Sales at Rs 8.73 crore, down 17.55% Y-o-Y
    moneycontrol.com
    NewsBot
    Aug 6 9:48 AM
    Parenteral Drug Consolidated June 2019 Net Sales at Rs 8.72 crore, down 82.24% Y-o-Y
    moneycontrol.com
    NewsBot
    Feb 15 9:37 AM
    NewsBot
    Nov 13 10:47 AM
    NewsBot
    Nov 13 10:42 AM
  • PDPL - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.